AR113254A1 - IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE - Google Patents
IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USEInfo
- Publication number
- AR113254A1 AR113254A1 ARP180102629A ARP180102629A AR113254A1 AR 113254 A1 AR113254 A1 AR 113254A1 AR P180102629 A ARP180102629 A AR P180102629A AR P180102629 A ARP180102629 A AR P180102629A AR 113254 A1 AR113254 A1 AR 113254A1
- Authority
- AR
- Argentina
- Prior art keywords
- angptl3
- irna agents
- compositions
- methods
- agents
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación se refiere a agentes de iARN, por ejemplo, agentes de iARN de cadena doble, capaces de inhibir la expresión del gen de la Angiopoyetina tipo 3 (también denominada ANGPTL3, ANGPL3, proteína angiopoyetina tipo 3), y composiciones que incluyen agentes de iARN de ANGPTL3. También se divulgan métodos para usar los agentes de iARN de ANGPTL3 y composiciones. Los agentes de iARN de ANGPTL3 divulgados en la presente pueden estar conjugados con ligandos de direccionamiento para facilitar la administración a células, inclusive a hepatocitos. También se describen composiciones farmacéuticas que incluyen uno o más agentes de iARN de ANGPTL3, opcionalmente con uno o más productos terapéuticos adicionales. La administración de los agentes de iARN de ANGPTL3 in vivo proporciona la inhibición de la expresión del gen ANGPTL3, y puede dar como resultado niveles de triglicéridos y/o niveles de colesterol reducidos en el sujeto. Los agentes de iARN se pueden usar en métodos de tratamiento de enfermedades y trastornos relacionados con ANGPTL3 que incluyen enfermedades cardiovasculares, tales como hipertrigliceridemia e hiperlipidemia.The present disclosure relates to iRNA agents, eg, double-stranded iRNA agents, capable of inhibiting the expression of the Angiopoietin type 3 gene (also referred to as ANGPTL3, ANGPL3, angiopoietin protein type 3), and compositions including agents iRNA of ANGPTL3. Methods for using the ANGPTL3 iRNA agents and compositions are also disclosed. The ANGPTL3 iRNA agents disclosed herein may be conjugated with targeting ligands to facilitate delivery to cells, including hepatocytes. Also disclosed are pharmaceutical compositions that include one or more ANGPTL3 iRNA agents, optionally with one or more additional therapeutics. Administration of ANGPTL3 iRNA agents in vivo provides for inhibition of ANGPTL3 gene expression, and can result in reduced triglyceride levels and / or cholesterol levels in the subject. IRNA agents can be used in methods of treating ANGPTL3-related diseases and disorders including cardiovascular diseases, such as hypertriglyceridaemia and hyperlipidemia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558819P | 2017-09-14 | 2017-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113254A1 true AR113254A1 (en) | 2020-03-11 |
Family
ID=70465584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102629A AR113254A1 (en) | 2017-09-14 | 2018-09-14 | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR113254A1 (en) |
-
2018
- 2018-09-14 AR ARP180102629A patent/AR113254A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20018305A (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE | |
| ECSP20017905A (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
| CO2018003678A2 (en) | Compositions and methods to inhibit lpa gene expression | |
| CO2017004728A2 (en) | Compositions and methods to inhibit the expression of the hao1 gene (hydroxy acid oxidase 1 (glycolate oxidase) | |
| CL2016003041A1 (en) | Isolated double stranded ribonucleic acids, pharmaceutical compositions comprising them and method for inhibiting the expression of the alas1 gene based on the administration of said composition. divisional application 2725-2014. | |
| GT201500330A (en) | COMPOSITIONS AND METHODS OF USE OF RNA INTERFERENCE IN SERPINE 1 | |
| EA201692318A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE | |
| ECSP20000655A (en) | IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENaC AND METHODS OF USE | |
| AR113254A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE | |
| AR113014A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
| AR106227A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) | |
| AR113454A1 (en) | IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 | |
| AR112754A1 (en) | IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF a-ENaC AND METHODS OF USE | |
| CR20200117A (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| EA202090687A1 (en) | RNAi AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
| AR104542A1 (en) | COMPOSITIONS OF ARNi AGAINST FACTOR XII (HAGEMAN FACTOR) (F12), CALICREIN B, PLASMATIC (FLETCHER FACTOR) 1 (KLKB1), AND QUININOGEN 1 (KNG1) AND METHODS OF USE OF THE SAME | |
| AR096390A1 (en) | COMPOSITIONS OF ARNi DE SERPINA1 AND ITS METHODS OF USE |